Lenalidomide in Relapsed or Refractory Multiple Myeloma
暂无分享,去创建一个
[1] B. Barlogie,et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.
[2] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[3] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[4] G. Morgan,et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.
[5] M. Dimopoulos,et al. The evolving role of lenalidomide in the treatment of hematologic malignancies , 2007, Expert opinion on pharmacotherapy.
[6] T. Choueiri,et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Vanderkerken,et al. Immunomodulatory drugs as a therapy for multiple myeloma. , 2006, Current pharmaceutical biotechnology.
[8] Michael L. Wang,et al. Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). , 2006 .
[9] S. Trudel,et al. Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels. , 2006 .
[10] Michael L. Wang,et al. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. , 2006 .
[11] L. Kmet,et al. Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial. , 2006 .
[12] Michael L. Wang,et al. Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. , 2006 .
[13] S. Trudel,et al. Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma. , 2006 .
[14] R. Foà,et al. Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. , 2006 .
[15] H. Einsele,et al. Lenalidomide (Revlimid™), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple Myeloma - First Results of a German Multicenter Phase I/II Trial. , 2006 .
[16] S. Jagannath,et al. Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. , 2006 .
[17] G. Morgan,et al. Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients. , 2006 .
[18] Diane Warren,et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.
[19] A. Dispenzieri,et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. , 2006, Archives of dermatology.
[20] S. Jagannath,et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.
[21] John Crowley,et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. , 2006, Blood.
[22] Shaji K. Kumar,et al. Thalidomide and lenalidomide in the treatment of multiple myeloma. , 2006, European journal of cancer.
[23] K. Anderson,et al. Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Zeldis,et al. Lenalidomide and venous thrombosis in multiple myeloma. , 2006, The New England journal of medicine.
[25] H. Goldschmidt,et al. A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma , 2006, British journal of haematology.
[26] Robert A Kyle,et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.
[27] S. Jagannath,et al. A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. , 2005 .
[28] John Crowley,et al. High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis. , 2005 .
[29] Kenneth C Anderson,et al. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. , 2005, Seminars in hematology.
[30] J. Miguel,et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma , 2004, Leukemia.
[31] M. Dimopoulos,et al. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Michael L. Wang,et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. , 2003, Seminars in hematology.
[33] A. Dalgleish,et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.
[34] Richard LeBlanc,et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.
[35] N. Munshi,et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.
[36] P. Richardson,et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications , 2001, Leukemia.
[37] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[38] J Shaughnessy,et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.
[39] M. Dimopoulos,et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] G. Morgan,et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.
[41] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[42] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[43] J. Zeldis,et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. , 1999, Clinical therapeutics.
[44] T. Schacker,et al. Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.
[45] B. Barlogie,et al. Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.
[46] B. Barlogie,et al. VAD‐based regimens as primary treatment for multiple myeloma , 1990, American journal of hematology.
[47] B. Barlogie,et al. High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.
[48] B. Barlogie,et al. Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.
[49] W. Vaughn,et al. Melphalan therapy for plasma cell myeloma. , 1968, Blood.